Navigation Links
Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
Date:6/3/2013

PARSIPPANY, N.J., June 3, 2013 /PRNewswire-USNewswire/ -- Today, Ferring Pharmaceuticals Inc. announced that it will donate $1M to the Alliance for Fertility Preservation (the Alliance), a newly formed 501c3 charitable organization established by and comprised of experts representing a broad range of disciplines. The Alliance helps to promote the education of patients diagnosed with cancer to enable them to make the best informed decisions regarding fertility preservation options prior to commencement of treatment and to better understand potential opportunities to help manage infertility after treatment.

According to survey responses from cancer survivors of childbearing age, less than half of patients recalled having a discussion of fertility or the effects their treatment might have on their future fertility upon being diagnosed with cancer.[i] Over 70,000 women in their twenties and thirties are diagnosed with various forms of cancer each year.[ii]

"As cancer survival rates increase, more and more patients need to consider their life after treatment, including how they might build or expand their family," said Joy Lewin , Director of Ferring's reproductive health unit. "Unfortunately, when faced with the overwhelming decisions surrounding their cancer diagnosis, future fertility is not top of mind.  We believe it's imperative to drive a better dialogue between healthcare providers and patients, which is why Ferring is supporting the Alliance in meeting this unmet need."

Formed in December 2011, the Alliance for Fertility Preservation, which was awarded 501c3 status on January 22, 2013 endeavors to promote a dialogue between patients and clinicians in an effort to optimize patient knowledge as to their expectations regarding fertility options as affected by their cancer care. The Alliance's unique, multidisciplinary approach with representation of experts in the fields of reproductive endocrinology, embryology, urology, oncology, psychology and reproductive law, will help the Alliance to address its goals.  

With the help provided by Ferring's donation, the Alliance will seek to develop educational tools to facilitate communication between patients and health care providers, work with healthcare systems to ensure they are equipped to provide patients with current and accurate information about fertility preservation and help to promote research in the field.

"Building on the American Society of Clinical Oncology's guidelines, the Alliance will work to identify different ways to assist physicians within different communities to help them educate their patients about fertility preservation and to provide support which enables patients to make informed decisions about their fertility options," said John Mulhall , M.D., Chairman of the Alliance for Fertility Preservation and urologist at Memorial Sloan Kettering Cancer Center.

Other members of the executive committee include:

  • Zev Rosenwaks, M.D., Alliance Vice Chairman, Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at New York-Presbyterian Hospital/ Weill Cornell Medical Center
  • Glenn Schattman , M.D., Alliance Secretary/Treasurer, Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at New York-Presbyterian Hospital/ Weill Cornell Medical Center
  • Leslie Schover , Ph.D., Alliance Executive Committee, University of Texas MD Anderson Cancer Center
  • Tessa Cigler , M.D., M.P.H., Alliance Executive Committee. Weill Cornell Medical College, Division of Medical Oncology

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urologygastroenterologyendocrinology and osteoarthritis. For more information, visit www.ferringUSA.com.

About the Alliance for Fertility Preservation
The Alliance for Fertility Preservation was formed to help facilitate a dialogue between clinicians and patients who have recently been diagnosed with cancer in the U.S. about the potential loss of fertility due to cancer treatment and the options for fertility preservation. The mission of the Alliance for Fertility Preservation (the Alliance) is to educate and empower patients diagnosed with cancer to make the best decisions regarding fertility preservation prior to treatment and infertility management after treatment. The Alliance also endeavors to promote dialogue between patients and clinicians in an effort to optimize expectations and care. For more information, visit www.fertilitypreservationalliance.org or call 1-877-760-4122.

[i] Lee SJ, Schover LR, Patridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24(3): 2917-2931.

[ii] http://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?applId=7616037&term=CA134197


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Extends Its Heart to Heart Video Contest
2. Ferring Pharmaceuticals Inc. Adopts Local Morristown Playground
3. Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
6. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
7. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
8. Ampio Pharmaceuticals Provides Clinical Updates
9. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
10. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
11. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
(Date:12/5/2016)... Ill. , Dec. 5, 2016 For ... score on the 2017 Human Rights Campaign Foundation,s ... The CEI is a national benchmarking tool used to ... bisexual, and transgender (LGBT) employee equality. For ... Survey to help companies gauge their equality efforts, culture ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... on perampanel presented at the 2016 Annual Meeting of ... marketed as FYCOMPA® CIII, is indicated as an adjunctive ... with or without secondarily generalized seizures and primary generalized ... 12 years of age and older. Please see Important ...
Breaking Medicine Technology:
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... Missouri (PRWEB) , ... December 05, 2016 , ... ... ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has always ... treatment accessible to as many people as possible. In that spirit, Castlewood ...
(Date:12/5/2016)... ... ... U.S. Apple Association (USApple) begins the holiday giving season by donating $17,800 to ... Buy an Apple, Help a Student fundraising campaign. , Winning ideas ... their families; solar technology to efficiently process compost; and iPads to enhance student learning. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... portfolio company, today announced it has acquired the assets of Frankfurt, Germany ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
Breaking Medicine News(10 mins):